FindTrial
Sign In

0.5% timolol maleate cream for the treatment of superficial infantile hemangioma with different height: a prospective, self controlled clinical trial

0.5% timolol maleate cream for the treatment of superficial infantile hemangioma with different height: a prospective, self controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017493
Enrollment
Unknown
Registered
2018-08-01
Start date
2019-02-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infantile hemangiomas

Interventions

0-0.5mm:0.5% timolol cream
0.6-1.0mm:0.5% timolol cream
1.1-1.5mm:0.5% timolol cream
1.6-2.0mm:0.5% timolol cream
>2.0mm:0.5% timolol cream

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School Of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: (1) the diagnosis of the superficial infantile hemangioma, the age of the patient was less than 6 months, and the male and female were not limited; (2) the superficial infantile hemangioma had not received any other treatment; (3) agreement to participate and signed informed consent was provided by the patients guardians.

Exclusion criteria

Exclusion criteria: (1) severe heart disease or asthma; (2) patients who had a history of allergies to ß-adrenergic receptor antagonist; (3) wounds in the lesion area, or patients with epidermal ulceration.

Design outcomes

Primary

MeasureTime frame
VAS;—

Countries

China

Contacts

Public ContactLi Wei

Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine

liweiboshi@163.com+86 13916936121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026